Loading
CMF Regimen / Triple Negative Breast Cancer / Breast Cancer · Phase 2 Trial
ClinicalTrials.gov · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered Phase 2 feasibility trial currently recruiting participants to evaluate whether dose-dense CMF chemotherapy can be delivered to breast cancer patients aged 70 and older. No results are posted in this registry record; the study measures completion of treatment cycles over 6 months as its primary outcome.
Phase 2, Interventional, Non Randomized, Parallel, Open label, Treatment purpose. Adenocarcinoma of the Breast, Breast Cancer, Triple Negative Breast Cancer; age from 70 Years. Intervention: Cohort 1; Cohort 2. Compared with: Paclitaxel (role and allocation not specified in registry record). n = 76. 7 sites: United States.
This is a registered Phase 2 feasibility trial currently recruiting participants to evaluate whether dose-dense CMF chemotherapy can be delivered to breast cancer patients aged 70 and older. No results are posted in this registry record; the study measures completion of treatment cycles over 6 months as its primary outcome.
No baseline characteristics, safety data, or efficacy endpoints are reported in this record.
Clinicians should recognize this as an ongoing feasibility study; no clinical evidence is available yet from this registry record. Results, when published, will inform whether dose-dense CMF is tolerable in older patients, not whether it is effective.
This is an active Phase 2 feasibility trial with no reported results; it examines whether a chemotherapy regimen can be delivered to older patients, a process measure rather than a clinical outcome.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize this as an ongoing feasibility study; no clinical evidence is available yet from this registry record. Results, when published, will inform whether dose-dense CMF is tolerable in older patients, not whether it is effective.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07768436). This is a study registration, not published results. Lead sponsor: Memorial Sloan Kettering Cancer Center. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 76 participants (ESTIMATED). Conditions: Adenocarcinoma of the Breast, Breast Cancer, Triple Negative Breast Cancer. Interventions: DRUG: CMF Regimen; DRUG: Paclitaxel. Primary outcome measures: Number of participants who have completed all four cycles of CMF , 6 months. Brief summary: The purpose of this study is to find out if it is practical (feasible) to give dose-dense CMF (cyclophosphamide, methotrexate, and fluorouracil) in two standard chemotherapy regimens in people with breast cancer, age 70 and older.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.